Columbia Endocrinology — Heidi Guzman, MD
180 Fort Washington Ave Ste 904 · New York, NY 10032
TelehealthAccepts insuranceCash pay
Listing updated Oct 2, 2026
KHADEEN CHEESMAN, M.D. pending 05/2011
KHADEEN CHEESMAN, M.D. pending 05/2011 · 5 E 98TH ST · New York, NY 10029
4.9· 12 Google reviews
Listing updated October 2, 2026
Retatrutide outlook for this practice
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
About this practice
The official website for KHADEEN CHEESMAN, M.D. pending 05/2011 in New York, NY did not load (http 403), so this summary cannot be grounded in first-party page content. No medications, prices, or services are inferred from the directory dump.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Yes |
| Cash pay accepted | — |
| Accepts insurance — per practice website | — |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
★ 4.9
Google rating · 12 reviews
9
reviews in the past year (avg ★ 5.0)
Counts computed by RetaMaps from public Google reviews; most recent review 2026-07-23. Read the reviews themselves on the practice's Google listing.
Clinicians
- KHADEEN CHEESMAN, M.D. pending 05/2011
Nearby providers in New York City
Weill Cornell Endocrinology — David J. Brillon, MD
525 E 68th St # F-2020 · New York, NY 10065
3.0(22 Google reviews · 6 in past year)
Accepts insuranceCash pay
Listing updated Oct 2, 2026
NYU Langone Diabetes & Endocrine Associates — Karin A. Katz, MD
222 East 41st Street, Floor 23 · New York, NY 10017
2.7(7 Google reviews · 1 in past year)
Accepts insuranceCash pay
Listing updated Oct 2, 2026
Kristen Decarlo, M.D.
423 E 23RD ST · New York, NY 10010
Listing updated Oct 2, 2026
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs